Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling-Reference-Cited by-同舟云学术

Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling

Published:2021-02 Issue:8 Volume:34 Page:108765
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Wang Hao^ORCID,Hou Wei,Perera Aldeb^ORCID,Bettler Carlee,Beach Jordan R.,Ding Xianzhong,Li Jun,Denning Mitchell F.,Dhanarajan Asha,Cotler Scott J.,Joyce Cara^ORCID,Yin Jun^ORCID,Ahmed Fowsiyo,Roberts Lewis R.^ORCID,Qiu Wei

Funder

National Institutes of Health

American Cancer Society

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference96 articles.

1. AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells;Abdelhamed;J. Cancer,2016

2. Mechanism of activation of protein kinase B by insulin and IGF-1;Alessi;EMBO J.,1996

3. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC;Amato;J. Clin. Invest.,2014

4. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer;Amato;Cancer Res.,2016

5. EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes;Andl;Am. J. Physiol. Gastrointest. Liver Physiol.,2004

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the EphA2 pathway: could it be the way for bone sarcomas?;Cell Communication and Signaling;2024-09-09

2. Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies;Journal of Hematology & Oncology;2024-09-04

3. Catalpol ameliorates liver fibrosis inhibiting aerobic glycolysis by EphA2/FAK/Src signaling pathway;Phytomedicine;2024-09

4. Comprehensive analysis of EphA2 in pan‐cancer: A prognostic biomarker associated with cancer immunity;Clinical and Experimental Pharmacology and Physiology;2024-06-17

5. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer;International Journal of Molecular Sciences;2024-01-20